{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:44:13Z","timestamp":1769600653973,"version":"3.49.0"},"reference-count":138,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2026,1,2]]},"DOI":"10.1080\/14740338.2025.2543457","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T17:50:55Z","timestamp":1755712255000},"page":"71-87","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Updates on immunosuppressant safety and malignancy risk in patients with multiple sclerosis"],"prefix":"10.1080","volume":"25","author":[{"given":"Gloria","family":"Dalla Costa","sequence":"first","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giancarlo","family":"Comi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]},{"name":"Casa di Cura Igea","place":["Milan, Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32388-1"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000560"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03116"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa145"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92286-6"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003982.pub2"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-5101.2003.00721.x"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.46.6.1607"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/35.8.738"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H219"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-826853"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1191\/135248506ms1307cr"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.1.20"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.8.1018"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00838165"},{"key":"e_1_3_4_17_1","first-page":"6","volume-title":"Recent advances in multiple sclerosis therapy","author":"Ghezzi A","year":"1989","unstructured":"Ghezzi A, DiFalco M, Locatelli C, et al. Clinical controlled randomized trial of azathioprine in multiple sclerosis. In: Consette R, Delmotte P, editors. Recent advances in multiple sclerosis therapy. Amsterdam: Elsevier; 1989. p. 6."},{"key":"e_1_3_4_18_1","unstructured":"The Australian Adverse Drug Reactions Bulletin. Drug induced pancreatitis. [cited 2025 Jan 12]. Available from: https:\/\/www.tga.gov.au\/sites\/default\/files\/aadrb-0612.pdf"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1191\/1352458502ms790oa"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.02.008"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.2.599"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-003-1089-x"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.54.12.1055"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380815"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90490-6"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)63185-9"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880201)61:3<451::AID-CNCR2820610308>3.0.CO;2-G"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03720140043031"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-5-199309010-00003"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-7-199610010-00003"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.291.6507.1457"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V68.5.1114.1114"},{"issue":"4","key":"e_1_3_4_33_1","first-page":"807","article-title":"The purine path to chemotherapy","volume":"13","author":"Elion GB","year":"1993","unstructured":"Elion GB. The purine path to chemotherapy. Biosci Rep. 1993;13(4):807\u2013821.","journal-title":"Biosci Rep"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.07.059"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI16432"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-79-5-694"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)24030-4"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2004.04.022"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c1786"},{"issue":"8","key":"e_1_3_4_40_1","first-page":"733","article-title":"Comparison of azathioprine and interferon beta-1b in the management of relapsing-remitting multiple sclerosis: a randomized clinical trial","volume":"109","author":"Etemadifar M","year":"2007","unstructured":"Etemadifar M, Janghorbani M. Comparison of azathioprine and interferon beta-1b in the management of relapsing-remitting multiple sclerosis: a randomized clinical trial. Clin Neurol Neurosurg. 2007;109(8):733\u2013738.","journal-title":"Clin Neurol Neurosurg"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015005.pub2"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.12.1843"},{"issue":"9","key":"e_1_3_4_43_1","first-page":"1113","article-title":"Randomized study of weekly interferon beta-1a and azathioprine in relapsing-remitting multiple sclerosis","volume":"15","author":"Havrdova E","year":"2009","unstructured":"Havrdova E, Zivadinov R, Genovese AV, et al. Randomized study of weekly interferon beta-1a and azathioprine in relapsing-remitting multiple sclerosis. Mult Scler. 2009;15(9):1113\u20131126.","journal-title":"Mult Scler"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI3125"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420307"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.10.036"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198301273080401"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.5.910"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.05.073"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05052-1"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1191\/1352458503ms926oa"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)12023-X"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000095425.84407.39"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181dc1ae0"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318238ee00"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002745"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-005-0839-3"},{"key":"e_1_3_4_58_1","first-page":"bcr06","article-title":"Early mitoxantroneinduced cardiotoxicity in secondaryprogressive MS","volume":"2009","author":"Paul F","year":"2009","unstructured":"\u202fPaul F, D\u00f6rr J, W\u00fcrfel J. Early mitoxantroneinduced cardiotoxicity in secondaryprogressive MS. BMJ Case Rep. 2009;2009:bcr06.","journal-title":"BMJ Case Rep"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518771875"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-012-6775-0"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517727603"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70005-5"},{"key":"e_1_3_4_64_1","first-page":"157167","article-title":"Integrated safety of cladribine tablets in MS","volume":"29","author":"Cook S","year":"2019","unstructured":"\u202fCook S, Leist T, Comi G. Integrated safety of cladribine tablets in MS. Mult\u202fscler\u202frelat\u202fdisord. 2019;29:157167.","journal-title":"Mult\u202fscler\u202frelat\u202fdisord"},{"key":"e_1_3_4_65_1","first-page":"175628641988759","article-title":"Cladribine is effective and safe after natalizumab","volume":"12","author":"M\u00f6hn N","year":"2019","unstructured":"M\u00f6hn N, Skripuletz T, S\u00fchs KW, et\u202fal. Cladribine is effective and safe after natalizumab. Ther\u202fadv\u202fneurol\u202fdisord. 2019;12:1756286419887596.","journal-title":"Ther\u202fadv\u202fneurol\u202fdisord"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.01.038"},{"key":"e_1_3_4_67_1","first-page":"175628642092268","article-title":"Longterm effectiveness of cladribine tablets: Italian registry (CLARINETMS)","volume":"13","author":"Patti F","year":"2020","unstructured":"\u202fPatti F, Visconti A, Capacchione A. Longterm effectiveness of cladribine tablets: Italian registry (CLARINETMS). Ther\u202fadv\u202fneurol\u202fdisord. 2020;13:1756286420922685.","journal-title":"Ther\u202fadv\u202fneurol\u202fdisord"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520921087"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000477"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61769-3"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61768-1"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.7224\/1537-2073.2014-030"},{"key":"e_1_3_4_73_1","unstructured":"European Medicines Agency. LEMTRADA (alemtuzumab) summary of product characteristics. [cited 2025 Jan 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lemtrada-epar-product-information_en.pdf"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104030"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231194823"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004313"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004354"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160714669"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1177\/13524585211061335"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1969850"},{"key":"e_1_3_4_81_1","unstructured":"European Medicines Agency. Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing. 2019 [cited 2024 Dec 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing_en.pdf"},{"key":"e_1_3_4_82_1","unstructured":"European Medicines Agency. Lemtrada for multiple sclerosis: measures to minimise risk of serious side effects. 2020 [cited 2024 Dec 12]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/lemtrada-article-20-procedure-lemtrada-multiple-sclerosis-measures-minimise-risk-serious-side_en.pdf"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-022-01832-4"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-019-01105-7"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-0922-z"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005420"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003379"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005417"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.22771"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005516"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-017-0557-4"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601277"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181e24373"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706383"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61649-8"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000125"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917246"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1459560"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520918375"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21867"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25927"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.94.15_supplement.3971"},{"key":"e_1_3_4_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.01.006"},{"key":"e_1_3_4_104_1","unstructured":"Genentech Inc. RITUXAN (rituximab): highlights of prescribing information. 1997."},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-018-0615-7"},{"key":"e_1_3_4_106_1","unstructured":"Remaly J. Report details first case of PML with ocrelizumab alone. Medscape; 2020 Apr 30 [cited 2025 Jan 12]. Available from: https:\/\/www.medscape.com\/viewarticle\/929728?nlid=135330_3405&src=WNL_mdplsnews_200501_mscpedit_neur&uac=129052CV&spon=26&impID=2366701&faf=1"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59406-4"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy356"},{"key":"e_1_3_4_109_1","unstructured":"Novartis Pharmaceuticals Corporation. ARZERRA (ofatumumab): highlights of prescribing information. 2009 [cited 2025 Jan 12]. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/arzerra.pdf"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606468"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25701"},{"key":"e_1_3_4_112_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3762864"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.124958"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507085759"},{"key":"e_1_3_4_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(90)90237-F"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.136.8.2747"},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.4.1.17"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.11.1572"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.5.1145"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-020-00749-x"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-9070-x"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-015-7653-3"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-018-8871-2"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09195-2"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000320"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-016-0058-0"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0676"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37878"},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000635"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18061249"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2018.08.001"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.059238"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.01.042"},{"key":"e_1_3_4_135_1","unstructured":"Center For Drug Evaluation and Research. Ocrelizumab (internal FDA review). 2016 [cited 2025 Jan 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761053orig1s000medr.pdf"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key428"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8010012"},{"key":"e_1_3_4_138_1","unstructured":"Genentech Inc. OCREVUS (ocrelizumab): highlights of prescribing information. 2017 [cited 2025 Jan 12]. Available from: https:\/\/www.gene.com\/download\/pdf\/ocrevus_prescribing.pdf"},{"key":"e_1_3_4_139_1","unstructured":"Novartis Pharmaceuticals Corporation. KESIMPTA (ofatumumab): highlights of prescribing information. 2020 Aug [cited 2025 Jan 12]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125326s070lbl.pdf"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2025.2543457","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T14:04:05Z","timestamp":1767362645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2025.2543457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":138,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,2]]}},"alternative-id":["10.1080\/14740338.2025.2543457"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2025.2543457","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}